Form 8-K · Current Report · Filed 2026-05-11
Halozyme Announces New $1 Billion Share Repurchase Program and Reports Q1 2026 Results
Halozyme Therapeutics, Inc. announced a new $1 billion share repurchase program and reported its financial results for the first quarter of 2026. The company's total revenue increased by 42% year-over-year to $377 million, driven by a 43% increase in royalty revenue to $241 million. Halozyme reiterated its 2026 financial guidance, projecting total revenue between $1.710 billion and $1.810 billion, with royalty revenue expected to exceed $1 billion for the full year. The company also highlighted recent collaboration agreements and the potential for new royalty revenue opportunities from its ENHANZE and Hypercon technologies.
- Filer
- Halozyme Therapeutics Inc. HALO · NASDAQ
- Filed
- Accession
- 0001159036-26-000067
- CIK
- 0001159036
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$64.12
Next session
+10.6%
Since filing
+71.9%
Latest close
$110.24
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from HALO reporting the same item, with the next session's move:
Insider tape
Within 45 days of this filing, HALO insiders reported 3 Form 4 transactions — net selling of $189K.
About Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc. is a biopharmaceutical company that specializes in developing and commercializing treatments focused on enhanced subcutaneous drug delivery. The company's proprietary technology, ENHANZE, aims to improve the efficacy and convenience of existing therapies by facilitating faster drug absorption and reducing the need for intravenous administration. Halozyme partners with major pharmaceutical companies to integrate its technology with a variety of treatments, significantly impacting the oncology, immunology, and genetic disorder sectors. This collaboration model helps expand the reach of its technology across multiple therapeutic applications. Based in San Diego, California, Halozyme is noted for its innovative approach to drug delivery, contributing to the broader pharmaceutical industry's efforts to improve patient experiences and optimize medical outcomes. As a significant player in the biopharmaceutical landscape, Halozyme's advancements continue to drive interest and growth within the market, underscoring the vital role of drug delivery technology in modern medicine.
Never miss another HALO filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.